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Abstract 
High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, 
and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine 
carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line 
chemotherapy is presented. A 29-year-old male with a huge liver tumor was diagnosed 
with high-grade neuroendocrine carcinoma originating from the liver. Multiple liver and 
bone metastases were found one month after surgery. He was treated with three 
chemotherapy regimens used for the management of small-cell lung cancer with 
extensive disease. However, none of them could be maintained because of tumor 
progression. He was then treated with bevacizumab plus modified FOLFOX6 as the 
fourth-line regimen. Dramatic tumor shrinkage was obtained, and a partial response was 
achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated 
with bevacizumab in combination with cytotoxic chemotherapy. Case Rep Oncol 2011;4:260–266 
DOI: 10.1159/000328802 
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Introduction 
Neuroendocrine carcinoma is classified pathologically into three broad categories 
based on the grade of differentiation: low grade (well differentiated), intermediate grade 
(moderately differentiated), and high grade (poorly differentiated) [1]. The high-grade 
malignancies are aggressive and usually require combined multimodality treatment. 
When metastatic lesions are present, first-line systemic chemotherapy with a platinum-
based regimen that is used in the management of small-cell lung cancer is recommended 
[2]. A study explored infusional cisplatin and etoposide in 53 patients with metastatic 
high-grade neuroendocrine carcinoma [3]; the response rate was 42%, and the response 
duration and median survival were 9 months and 15 months, respectively. 
Here, a case with high-grade neuroendocrine carcinoma that improved with 
bevacizumab plus modified FOLFOX6 (mFOLFOX6) as the fourth-line chemotherapy is 
presented. 
Case Report 
A 29-year-old male with a huge liver tumor was admitted to the Hokkaido University Hospital. The 
patient had been in good health until two weeks earlier when he felt sudden abdominal pain. On 
physical examination, an abdominal mass was palpable in the right upper quadrant. A computed 
tomography (CT) and 
18F-fluorothymidine-positron emission tomography (PET) scan revealed a huge 
liver tumor (over 10 cm) and lymph node metastases (fig. 1). There was no evidence of hepatitis B or C 
virus infection, and he did not have a history of excessive alcohol consumption and smoking. Upper and 
lower gastrointestinal endoscopy revealed no abnormality. As he had enough visceral function, an 
extended right lobe hepatectomy was performed. Histopathological examination revealed high-grade 
neuroendocrine carcinoma originating from the liver (fig. 2). The pathological stage was pT4N1M0, 
pStage IVA. Despite surgery, multiple liver and bone metastases were found on the follow-up 
examination one month after surgery. Treatment as for small-cell lung cancer with extensive-stage 
disease was then chosen. Zoledronic acid and palliative radiotherapy were given for bone metastases. 
For systemic therapy, he received three chemotherapy regimens used for the management of small-cell 
lung cancer: two courses of cisplatin plus irinotecan as the first line, two courses of amrubicin as the 
second line, and one course of topotecan as the third line. However, none of them could be maintained 
because of aggressive tumor progression. 
Usual cytotoxic chemotherapies were thought to be ineffective. However, his Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) was well maintained (PS 1), and he and his family 
strongly wished to receive more systemic chemotherapy using other drugs. Therefore, bevacizumab, 
anti-vascular endothelial growth factor (VEGF) antibody, plus mFOLFOX6 was chosen as his fourth-
line regimen. The dose and administration schedule were as follows: bevacizumab 5 mg/kg in 30 min, 
oxaliplatin 85 mg/m
2 in 2 h, L-leucovorin 200 mg/m
2 in 2 h, 5-FU 400 mg/m
2 in 5 min, and continuous 
5-FU 2,400 mg/m
2 in 46 h. The therapy was given every two weeks. After four cycles of this 
chemotherapy regimen, the metastases shrank markedly (fig. 3). No adverse events related to 
bevacizumab were observed. This treatment was continued for eight cycles, and then followed by a 
regimen without oxaliplatin (i.e. bevacizumab plus simplified LV5FU2 regimen) because of oxaliplatin-
related neurotoxicity. The treatment interval was modified from every two weeks to every three weeks 
because of thrombocytopenia. Tumor shrinkage continued for over ten months, during which 
bevacizumab was continued. The patient is still alive at over two years from his first visit, and is 
continuing bevacizumab in combination with cytotoxic chemotherapy. Case Rep Oncol 2011;4:260–266 
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Discussion 
Since neuroendocrine cells are distributed widely throughout the body, 
neuroendocrine neoplasms can occur in various organs. High-grade neuroendocrine 
carcinomas can originate for example in the gastrointestinal tract, bladder, cervix or 
prostate. Cho et al. [4] reviewed prospectively maintained databases from two institutions 
of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 
and 2006. Only 10% of 70 patients had high-grade disease. The patient in this case report 
was diagnosed on histopathological examination as neuroendocrine carcinoma 
originating from the liver. In addition, the tumor was more aggressive than most 
neuroendocrine carcinomas (the MIB-1 index was about 70%), and was classified as high-
grade neuroendocrine carcinoma. Systemic surveys revealed no other primary site. This 
diagnosis is thought to be correct because the patient has shown no evidence of another 
primary site of neuroendocrine carcinoma over two years from diagnosis. 
This case report suggests that high-grade neuroendocrine carcinomas can be treated 
with bevacizumab in combination with cytotoxic agents. It is plausible that mFOLFOX6 
rather than bevacizumab was effective for this patient. However, cisplatin, a platinum-
containing drug similar to oxaliplatin, had already been used in the first-line 
chemotherapy. 5-FU was used for the first time in this fourth-line regimen, but is not 
recommended in the guideline for small-cell lung cancer [5]. On the other hand, a phase 
II study reported the efficacy and safety of bevacizumab plus cisplatin and etoposide in 
previously untreated patients with extensive-disease small-cell lung cancer [6]. The 
addition of bevacizumab to cytotoxic chemotherapy improved progression-free survival 
(PFS) and overall survival (OS) compared with historical controls who had received this 
chemotherapy regimen without bevacizumab. In this study, PFS and OS were 4.7 and 10.9 
months, respectively. Toxicities increased minimally compared with chemotherapy alone 
in this study. Because bevacizumab was approved only for metastatic colorectal cancer in 
Japan at the time of first administration of bevacizumab for this patient (July 2009), we 
had to choose the mFOLFOX6 or FOLFIRI regimen (using irinotecan instead of 
oxaliplatin) as combination chemotherapy in order to use bevacizumab. Additionally, 
there are no definite noninvasive biomarkers of anti-VEGF therapy. Current evidence 
indicates only some predictive value for hypertension, vascular imaging, and VEGF gene 
polymorphisms as potential biomarkers [7]. To the best of our knowledge, there are no 
reports about the effectiveness of bevacizumab or mFOLFOX6 in high-grade 
neuroendocrine carcinoma. In this case report, the addition of bevacizumab seemed to be 
effective even after the patient was heavily treated with cytotoxic chemotherapy. 
Angiogenesis is a fundamental event in tumor growth and metastasis. VEGF is a key 
regulator of angiogenesis. The addition of bevacizumab, a monoclonal antibody against 
VEGF, to standard cytotoxic agents is reported to increase overall survival in non-small-
cell lung cancer (non-squamous cell carcinoma) and colorectal cancer. The clinical 
efficacy of bevacizumab in other kinds of cancers still remains to be studied. In preclinical 
experiments, sustained VEGF inhibition has been shown to achieve and maintain tumor 
regression [8]. Also in the clinical setting, one observational study suggested that 
sustained VEGF inhibition could be effective in colorectal cancer [9]. In advanced 
neuroendocrine carcinoma, targeting therapies seem to be the best real hope for 
treatment because of insufficiency of conventional cytotoxic chemotherapeutic agents. 
The rationale behind their investigation is that neuroendocrine carcinomas are highly Case Rep Oncol 2011;4:260–266 
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vascular and have been shown to express several angiogenic factors including VEGF [10]. 
Future clinical studies are required to confirm the efficacy of bevacizumab in the 
treatment for high-grade neuroendocrine carcinoma. 
Disclosure Statement 
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Fig. 1. a CT scan at the first visit. A huge tumor (over 10 cm) is seen in the right liver lobe, along with 
liver metastasis and lymph node swelling. b 
18F-FDG-PET scan at the first visit. No distant metastases 
were detected. The primary lesion was thought to be in the liver. 
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Fig. 2. Histopathological examination reveals high-grade neuroendocrine carcinoma. a Hematoxylin 
and eosin staining shows tumor cells are characterized by a solid and trabecular architecture. The 
forming of rosettes are seen (arrowheads). Tumor cells have nuclear pleomorphism and granular 
cytoplasm. b Chromogranin A immunostaining is seen in almost all carcinoma cells. c The MIB-1 
index is about 70% in the lesion with the highest value. d TTF-1 immunostaining is negative. 
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Fig. 3. a, b CT scan prior to chemotherapy with bevacizumab plus mFOLFOX6. Three cytotoxic 
regimens for small-cell lung cancer with extensive-stage disease have been given by this point. c, d CT 
scan after four cycles of bevacizumab plus mFOLFOX6. Liver metastases are markedly smaller 
compared with those before the treatment with this regimen. 
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